The company’s positive first-in-human clinical study results indicate the safety and feasibility of their innovative system for removing blood clots in patients with acute pulmonary embolism.
Magneto, which began in Incentive, Peregrine Ventures Incubator, plans to continue developing and testing proprietary thrombectomy solutions for the treatment of ischemic strokes and pulmonary embolisms that will benefit hundreds of thousands of people a year in the US alone.
